Houston's most promising health tech startups lead innovation news to know

Houston health tech startup secures $20M series A, NIH grant amid clinical trials

fresh funding

A clinical-stage Houston health tech company with a novel therapeutic device has raised venture capital funding and secured a grant from the National Institutes of Health.

VenoStent Inc., which is currently in clinical trials with its bioabsorbable perivascular wrap, announced the closing of a $20 million series A round co-led by Good Growth Capital and IAG Capital Partners. The two Charleston, South Carolina-based firms also led VenoStent's 2023 series A round that closed last year at $16 million.

Additionally, the company secured a $3.6 million Small Business Innovation Research (SBIR) Phase II Grant from NIH, which will help fund its multi-center, 200-patient, randomized controlled trial in the United States.

Tim Boire, VenoStent CEO and co-founder, describes 2024 so far as "a momentous year" so far for his company.

"In the span of a few months, we initiated our first clinical sites, enrolled the first patients in our large RCT and closed our Series A with Norwest," Boire says in a news release. "We also received the NIH grant, which enables us to execute our trial with the highest degree of quality and rigor to make it as scientifically robust and impactful to patients as possible.

'Each of these are major company milestones that collectively represent many years of intensive and fruitful R&D and collaboration," he continues. "These recent milestones will propel our company forward to an exciting next phase."

Tim Boire is the CEO and co-founder of VenoStent. Photo via LinkedIn

The company's innovation, the SelfWrap, goes around arteriovenous (AV) access sites at the time of AV fistula creation surgery. The device is intended "to accelerate the usability and increase the durability of the fistula sites for chronic kidney disease (CKD) patients requiring hemodialysis," reads the release, "mimicking the arterial environment in veins, which experience a 10x increase in pressure and flow during AV creation and causes the veins to become unusable in dialysis."

Along with the investment, VenoStent announced two new board observers. Norwest General Partner Dr. Zack Scott and Investor Dr. Ehi Akhirome are bringing their expertise to the growing company.

"Norwest's investment is tremendous validation for VenoStent, and we are thrilled to have both Zack and Ehi joining the company's board," VenoStent COO and Co-Founder Geoffrey Lucks adds in the release. "Zack and Ehi have extensive knowledge in our space, and their added value will match the capital and cache of Norwest dollar-for-dollar."

Last year at the same time VenoStent announced its last funding round, the SelfWrap was approved by the U.S. Food and Drug Administration to begin its U.S. Investigational Device Exemption (IDE) study.

"Over half a million people in the U.S. rely on hemodialysis to survive and require an arteriovenous fistula creation surgery in order to receive the treatment. However, the AV fistula procedure has a one-year failure rate of more than 60 percent, which significantly impacts patients' survival rates and quality of life," Scott says in the release. "VenoStent's groundbreaking technology for AV fistula formation, SelfWrap, has the potential to significantly improve these odds. We look forward to working with the VenoStent team as it proves the efficacy of this breakthrough technology in order to improve the lives of hundreds of thousands of CKD patients."

Last summer, Boire told InnovationMap on the Houston Innovators Podcast that he's looking to launch the product in 2026.

Jessica Traver Ingram, CEO and co-founder of IntuiTap, joins the Houston Innovators Podcast to share her company's latest milestone. Photo courtesy of IntuiTap

With FDA approval, Houston health tech company prepares nationwide deployment

Houston innovators podcast episode 232

Jessica Traver Ingram has been captivated by the intersection of physics and health care for most of her life, and that passion led her to contributing to the establishment of the Texas Medical Center's Biodesign Fellowship. After helping make the program a reality, Traver Ingram then participated in it as a fellow.

The program selects fellows and then lets them explore the TMC's member institutions to find ways to innovate within unmet clinical needs, and the inefficiency and challenges with placing epidurals and lumbar punctures caught Traver Ingram and her cohort's eye. The process relies completely on the health care practitioner's ability to feel the spine with their fingers to make the injection.

"We kept watching the inefficiencies of these procedures, and everyone was like, 'you're right, we don't really know why we do it this way,'" Traver Ingram says on the Houston Innovators Podcast. "It's really cool to be outsiders watching and observing, because you just see things other people don't see — and that's in any industry."

With that, IntuiTap was born. Traver Ingram describes its tool, the VerTouch, as a "stud finder for the spine." After years of growing the company, she can also now call it FDA-approved.

"FDA clearance allows us to market the device in the United States, so we are entering the commercial launch stage of the company, which is really exciting," Traver Ingram says. "We plan to have these devices available in hospitals across the country within the year."

First up is what Traver Ingram calls a soft launch. The company is picking five institutions that want to be centers of excellence for the device and doing trial launches there before entering into a greater, nationwide rollout.

"It's just crazy that what started as just an idea on paper is now FDA approved and commercially ready and something that patients can see in hospitals this year," Traver Ingram says.

And the timing is important, she explains, adding that where the health care industry seems to be at as a whole is primed for innovation like IntuiTap.

"There's a lot of really exciting developments happening in health care right now," Traver Ingram says. "I feel like we're really at a tipping point for innovation and we're going to see some really big leaps in the next couple of years.

"One of the exciting trends I think that we're seeing is a shift away from blind procedures or procedures that are seen as an art requiring a significant amount of skills toward more science-based, safer, consistent, and repeatable procedures," she continues. "We fit really well into that category, so I'm glad that we're seeing that shift."

Mara McFadden (left), CEO of Endolumik, took home the top prize at the Ignite Fire Pitch Competition. Photo courtesy of Ignite

Houston organization doles out over $775,000 in prizes to women-led health tech startups

and the winner is

After virtual and postponed events, Ignite Healthcare Network finally got to honor its 2021 cohort and name the annual winners.

The Fifth Annual Fire Pitch Competition was slated to take place last November, but was postponed to January. Affected by the Delta and then Omicron variants of COVID-19, the event finally got to return to in-person networking and pitches on Thursday, March 3.

"The opportunity to bring people together is a really different level of engagement and energy," Ayse McCracken, founder and board chair of Ignite, says ahead of the awards event. "We love seeing the energy that's being generated in Houston around innovation — and particularly health care innovation."

Seven companies pitched and three were awarded monetary prizes. Morgantown, West Virginia-based Endolumik, which has developed a patent-pending fluorescence-guided device to improve visualization and safety of robotic and laparoscopic bariatric operations, took home the top prize, which included a total of $500,000 in investment prizes from the Texas Medical Center Venture Fund and Wavemaker Three-Sixty Health.

Second place was awarded to Rx Bandz of Locust Valley, New York. The company created the MiniJect, the world’s smallest military-grade auto-injector designed to deliver a wide range of injectable medication, and was awarded $250,000 from the Texas Halo Fund and $25,000 from The Southwest National Pediatric Device Innovation Consortium.

San Antonio-based Hera Biotech took third place and was awarded a pilot program prize with Banner Health. Hera has developed the first non-surgical, tissue-based test capable of diagnosing endometriosis.

Ignite taps into Houston health care institutions to provide opportunities for its cohort of companies. According to a news release, this year’s partner organizations included Houston Methodist, Memorial Hermann Health System, Texas Children’s Hospital, Texas Children’s Pediatrics, The Menninger Clinic, Banner Health, Kindred Healthcare, Aetna, Commonwealth Care Alliance, BLUE KC, Hospital for Special Surgery, Summit Health, TMC Ventures, Texas Heart Institute, Golden Seeds, Portfolia, The Artemis Fund, Wavemaker 360 Health, Prosalus Capital Partners, 7Wire Ventures, Texas Halo Fund, Unity Point Ventures and others.

The judges who evaluated the competition’s panel of companies included:

Jay Goss, MBA General Partner, Wavemaker Three-Sixty Health
Amanda Hammel, Chief Information Officer, Memorial Hermann Health System
Karen Hill, MD, MBA, SVP and Chief Medical Officer, Texas Children’s Health Plan
Tom Luby, PhD, Director, Texas Medical Center Innovation Institute
Fiona Mack, PhD, Head of JLABS @TMC
Roberta Schwartz, PhD, EVP and Chief Innovation Officer, Houston Methodist Hospital
Andrew Truscott, Global Health Technology Lead, Accenture

These five InnovationMap stories were the most read of 2021. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Here are Houston's top 5 health innovation stories of 2021

2021 in review

Editor's note: As 2021 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. When it came to the health care innovation and technology — whether it's a Q&A with a health tech entrepreneur or a digital health startup raising funds — in Houston, five stories trended among readers.

Fresh off a $1.4B exit, this Houston innovator is focused on funding medical device tech

Larry Lawson joined InnovationMap for a Q&A about his startup's recent exit, his role on the boards of five med device companies, his investment activity, and more. Photo courtesy of Larry Lawson

Earlier this year, Houston-based serial entrepreneur Larry Lawson celebrated the exit of his medical device company, Preventice Solutions, which he sold to Boston Scientific Boston Scientific in a $1.4 billion deal.

Nowadays, Lawson is laser focused on investing in the Houston innovation ecosystem, particularly in medical device, as well as working on Proxima Clinical Research, a contract research organization in the Texas Medical Center he co-founded with Kevin Coker.

Lawson joined InnovationMap for a Q&A about the exit, his role on the boards of five med device companies, and his investment activity. He also shares how he sees the impact of COVID-19 and where Houston's burgeoning innovation ecosystem is headed. Click here to read the full article.

Houston founder talks growth and innovation in the pharmaceuticals industry

Shaun Noorian, founder and CEO of Empower Pharmacy, joined InnovationMap for a Q&A on his rapidly growing compounding pharmacy business. Photo courtesy of Empower Pharmacy

When Shaun Noorian encountered what he felt was a poorly ran process, as an engineer, he built something better. Now, he runs one of the nation's largest compounding pharmacies that's at a pivotal time for growth.

Headquartered in Houston, Empower Pharmacy is opening two new facilities locally — one debuts later this year and the other in 2022. Ahead of this milestone for his company, Noorian joined InnovationMap for a Q&A about how he decided to start his company and how he's grown it from a small office to two 85,000-square-foot facilities — as well as how Houston has been a big part of his company's success. Click here to read the full article.

Report: Houston ranks among the worst cities for unnecessary medical treatments

Houston hospitals have been reported to have an excess of unnecessary health care tests and procedures. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston boasts of being home to the Texas Medical Center, the world's biggest medical complex. Yet Houston's medical community also holds a distinction that's hardly boast-worthy: It's the worst major metro area in Texas for unnecessary health care tests and procedures.

A study released May 4 by the Lown Institute, a health care think tank, shows hospitals in the Houston area collectively fare worse than their counterparts in Dallas-Fort Worth, San Antonio, and Austin for overuse of tests and procedures that the institute says offer little to no benefit.

To come up with its ranking, the institute looked at Medicare data for more than 1 million tests and procedures performed at over 3,100 U.S. hospitals from 2016 to 2018. Among the overused tests and procedures identified in the study are hysterectomy for benign disease, placement of coronary stents for stable heart disease, and diagnostic tests like head imaging for fainting.

"Overuse in American hospitals is a pervasive problem that needs to be addressed," Dr. Vikas Saini, president of the Lown Institute, says in a news release. "Hospitals want to do better, and these objective measures of performance can help them move forward." Click here to read the full article.

These are the 7 newest health tech companies to join TMCx

After a virtual bootcamp, the TMCx team selected seven startups to move forward in the accelerator. Photo courtesy of TMC

Last year, TMCx, the Texas Medical Center's health tech startup accelerator pivoted to digital programming.

The accelerator revamped its program to allow for an initial Bootcamp stage that would bring in a larger group of startups and then, after the boot camp, the program would move forward with a smaller group through the official acceleration process.

"We hosted 21 companies, representing six countries and 10 states, who each engaged with subject matter experts, clinical leaders, and corporate partners," writes Emily Reiser, senior manager of Innovation Community Engagement at TMC Innovation, in a blog post. "Over half of which ended Bootcamp in advanced discussions with hospitals and/or corporate partners." Click here to read the full article.

Houston biotech startup announces merger and $10M series A

A biotech startup focused on developing therapeutics for neurodegenerative and autoimmune diseases has some big news to share. Photo via Getty Images

A Houston company has emerged from stealth mode to announce a merger and a round of financing.

Coya Therapeutics, a clinical-stage biotech startup that focuses on creating therapeutics for neurodegenerative and autoimmune diseases, announced that it has completed a merger with Nicoya Health Inc. and raised $10 million in its series A. The round was led by Florida-based Allele Capital Partners LLC. Howard Berman, founder and board of directors for imaware, has been named CEO of Coya, as well as a member of the company's board of directors.

Coya's therapeutics uses innovative work from Dr. Stanley H. Appel, co-director of Houston Methodist Neurological Institute and Chair of the Stanley H. Appel Department of Neurology at Houston Methodist Hospital. The researcher has created a way to "isolate dysfunctional Tregs from a patient, convert them to a highly functional and neuroprotective condition, and expand these cells into the billions for intravenous reinfusion back to the patient," says Berman in a news release. This revolutionary work overcomes previous limitations in the field.

"I'm excited to have the opportunity to lead Coya at such an exciting and pivotal phase of growth," Berman says. "Through our sponsored research program in conjunction with Dr. Appel, we look forward to continuing advancement of this promising work and translating this work into a meaningful therapy for patients." Click here to read the full article.

These Houston startups have created health care-related solutions amid the coronavirus outbreak. Getty Images

These 7 Houston health tech companies are providing COVID-19 solutions

startups to the rescue

It's all hands on deck in Houston in the battle against coronavirus — and local biotech startups have risen to the occasion.

From mental health solutions and online portals to virtual medicine and new treatments, these Houston companies have recently launched or pivoted to new options in health care.

Mental Health Match

Ryan Schwartz is offering free counseling to Texans. Photo courtesy of Mental Health Match

Mental Health Match, a Houston-based startup that uses tech to easily connect people to mental health professionals, has announced the opportunity for 100 Texas residents to get their first appointment free and remotely.

The company cites data that shows:

A 78 percent increase in Texans who are concerned about their marriage
A 71 percent increase in Texans concerned with their parenting or their children
A 35 percent spike in Texans feeling panicked

"You might be practicing social distancing, but you are not alone. It is easier to make it through this together if you can get support and guidance from a skilled professional. That's why we're working with therapists across Texas to provide a free session to individuals who need it most," says Ryan Schwartz, founder of Mental Health Match, in a news release.

Texans can apply for the free sessions online on a first-come, first-served basis.

Medical Informatics Corp.

Medical Informatics Corp.'s Sickbay platform can monitor patients from afar. Photo via michealthcare.com

Houston-based Medical Informatics has created a virtual ICU program, called Sickbay, and the tech tool is being used to remotely monitor patients in Houston Methodist. The program works around the clock from a control hub to use artificial intelligence and algorithms to monitor patients.

The company, which recently moved into its office in TMCx+, announced major growth in January, just ahead of the coronavirus outbreak.

"We designed our Sickbay platform to give lost data back to doctors, nurses and other members of the care team so they could save more lives," says Vincent Gagne, vice president of product for MIC, in a news release. "In fact, our apps are built in collaboration with our clients, such as Texas Children's Hospital and Houston Methodist. Having these facilities blocks away from our headquarters accelerates that collaboration and development."

MolecularMatch

MolecularMatch is bringing together COVID-19 information and trials. Photo via molecularmatch.com

MolecularMatch, a Houston startup focused on clinical informatics, has launched a free portal that accumulates research and clinical trials for COVID-19. The company is a tenant of TMCx+ and a portfolio company of Houston-based venture capital group GOOSE.

"The number of therapeutic cures and vaccines being tested are growing at an astounding rate," says Eric Pulaski, CEO at MolecularMatch, in a news release. "Our tools make it easier for clinicians and patients to find the help they need. Hopefully, we can help save lives by shortening the time it takes to get more patients into clinical trials and by speeding up research to find cures and vaccines."

The product uses the company's artificial intelligence-backed curation platform and is updated every two to three days.

Luminare

Luminare Inc. pivoted to quickly create an online COVID-19 screening tool, and local governments have tapped into the resource. Andriy Onufriyenko/Getty Images

Founded in 2014, Houston-based health care software startup Luminare Inc. seeks to prevent sepsis, a life-threatening reaction to a host of infections that causes about one-third of U.S. hospital deaths. Recently, though, Luminare pivoted to address another health concern — the threat of the novel coronavirus.

After the novel coronavirus surfaced, Luminare retooled its sepsis-detection platform to create a free online self-assessment test for people who suspect they've contracted the virus. The test, available at CheckForCorona.com, helps someone figure out whether they should seek a coronavirus test.

An online screening typically takes less than two minutes. The confidential, secure assessment complies with guidelines from the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Based on your assessment results, you might be directed to contact your local health department or, in the worst-case scenario, call 911. Click here to read more.

Manatee

Manatee users can sign up for three months free. Photo via getmanatee.com

Denver-based Manatee was just announced to be selected for the 2020 TMCx cohort, and — while programming is beginning virtually — the startup will be enroute to Houston as soon as it's safe. Manatee focuses on providing connected, everyday therapy for kids.

In light of the effects of COVID-19 on both parents and children, Manatee has allowed users to register for three months free. Individuals can apply online.

Moleculin Biotech Inc.

Houston-based Moleculin, which works on oncology treatment, has filed a patent for its treatment to battle the coronavirus. Getty Images

Houston-based Moleculin Biotech Inc., a clinical stage pharmaceutical company that typically focuses on cancer treatment, announced that it has filed for a new patent for its use of one of its products to be used against the coronavirus and other potential viruses.

This patent application is for Moleculin's WP1122, and the company has entered into a partnership with a major Texas university to advance its research.

"We've actually been working on the antiviral potential of WP1122 for some time now," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "but the rise of COVID-19 has obviously placed a new sense of urgency on what we are doing. We hope to be generating animal data on WP1122's antiviral potential in the near term."

Pulmotech Inc.

Pulmotect, a clinical-stage biotechnology company based in Houston, is testing a drug that could be useful in mitigating the threats of the coronavirus, which is currently been recognized as a global health emergency. Getty Images

Experiments conducted by clinical-stage, Houston-based biotechnology company Pulmotect Inc. show its PUL-042 inhaled drug has proven effective in protecting mice against two types of coronavirus: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Researchers performed those tests at the University of Texas Medical Branch at Galveston.

In the Galveston experiments, a single inhaled dose of PUL-042 protected lab mice from the SARS virus, and it greatly reduced the amount of virus in their lungs after the mice became infected with SARS or MERS.

"With the risks of virulent coronaviruses and other threats increasing, as shown by the recent outbreak in Wuhan that has already spread from China to other countries including the United States, Pulmotect is optimistic that its immune-stimulating technology could be useful in mitigating the threats of current and emerging pathogens and protecting vulnerable populations," says CEO Dr. Colin Broom in a news release. Click here to read more.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

NASA names new chief astronaut based in Houston

new hire

NASA has a new chief astronaut. Scott Tingle, stationed at the space agency’s Johnson Space Center in Houston, assumed the post Nov. 10.

Tingle succeeds NASA astronaut Joe Acaba, who had been chief astronaut since February 2023. Acaba now works on the staff of the Johnson Space Center’s director.

As chief astronaut, Tingle runs NASA’s Astronaut Office. His job includes developing astronauts’ flight crew operations and assigning crews for space missions, such as Artemis missions to the moon.

Tingle, a former captain in the Navy, was named a NASA astronaut candidate in 2009. He has logged over 4,500 flight hours in more than 50 aircraft.

Tingle was a flight engineer aboard the International Space Station, where he spent 168 days in orbit during two expeditions that launched in December 2017. Since returning to Earth, he has held various roles in the Astronaut Office, including mission support, technical leadership and crew readiness.

Before joining NASA, Tingle worked in El Segundo, California, on the technical staff of The Aerospace Corp., a nonprofit that supports U.S. space programs.

Tingle recalls expressing his desire to be an astronaut when he was 10 years old. It took him four tries to be accepted by NASA as an astronaut candidate.

“The first time I figured it was kind of too early. The second application, they sent out some feelers, and that was about it. Put in my third application, and got a couple of calls, but it didn’t quite happen,” Tingle said in an article published on the website of Purdue University, his alma mater.

ExxonMobil officially pauses plans for $7B Baytown hydrogen plant

Change of Plans

As anticipated, Spring-based oil and gas giant ExxonMobil has officially paused plans to build a low-hydrogen plant in Baytown, Chairman and CEO Darren Woods told Reuters in late November.

“The suspension of the project, which had already experienced delays, reflects a wider slowdown in efforts by traditional oil and gas firms to transition to cleaner energy sources as many of the initiatives struggle to turn a profit,” Reuters reported.

Woods signaled during ExxonMobil’s second-quarter earnings call that the company was weighing whether it would move forward with the proposed $7 billion plant.

The Biden-era Inflation Reduction Act created a new 10-year incentive, the 45V tax credit, for production of clean hydrogen. But under President Trump’s "One Big Beautiful Bill Act," the window for starting construction of low-carbon hydrogen projects that qualify for the tax credit has narrowed. The Inflation Reduction Act mandated that construction start by 2033. But the Big Beautiful Bill switched the construction start time to early 2028.

“While our project can meet this timeline, we’re concerned about the development of a broader market, which is critical to transition from government incentives,” ExxonMobil Chairman and CEO Darren Woods said during the company’s second-quarter earnings call.

Woods had said ExxonMobil was figuring out whether a combination of the 45Q tax credit for carbon capture projects and the revised 45V tax credit would enable a broader market for low-carbon hydrogen.

“If we can’t see an eventual path to a market-driven business, we won’t move forward with the [Baytown] project,” Woods said.

“We knew that helping to establish a brand-new product and a brand-new market initially driven by government policy would not be easy or advance in a straight line,” he added.

ExxonMobil announced in 2022 that it would build the low-carbon hydrogen plant at its refining and petrochemical complex in Baytown. The company has said the plant is slated to go online in 2027 and 2028.

ExxonMobil had said the Baytown plant would produce up to 1 billion cubic feet of hydrogen per day made from natural gas, and capture and store more than 98 percent of the associated carbon dioxide. The plant would have been capable of storing as much as 10 million metric tons of CO2 per year.

---

This article originally appeared on EnergyCapitalHTX.com; it was updated to include new information about the plant in December 2025.

8 can't-miss Houston business and innovation events for December

where to be

Editor's note: Houston’s innovation scene is loading up the calendar before the holidays. From climatetech pitch days to the return of favorite festive shindigs, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Dec. 3 — SouthWest-Midwest National Pediatric Device Innovation Consortium

This annual event brings together members, colleagues and guests of the FDA-supported pediatric consortium who are dedicated to assisting device innovators throughout the lifecycle in delivering innovative solutions to patients. Featured speakers include Dr. Danielle Gottlieb from Le Bonheur Children's Hospital, Balakrishna Haridas from Texas A&M University and Dr. Chester Koh from Texas Children’s Hospital.

This event is Wednesday, Dec. 3, from 3:30-8 p.m. at Texas A&M EnMed Tower. Register here.

Dec. 4 — Resiliency & Adaptation Sector Pitch Day: Scaling Solutions to Address Climate Disruption

Join innovators, industry leaders, investors and policymakers as they explore breakthrough climate and energy technologies at Greentown's latest installment of its Sector Pitch Day series, focused on resiliency and adaptation. Hear from Adrian Trömel, Chief Innovation Officer at Rice University; Eric Willman, Executive Director of the Rice WaTER Institute; pitches from 10 Greentown startups and more.

This event is Thursday, Dec. 4, from 1-3:30 p.m. at the Ion. The Ion Holiday Block Party follows. Register here.

Dec. 4 — The Ion District Holiday Block Party

The Ion District, Rice Alliance and Greentown Labs will celebrate the season during the Ion District Holiday Block Party. Expect to find local bites, drinks, music and meaningful connections across Houston’s innovation ecosystem. Guests are invited to participate in Operation Love’s holiday toy drive supporting local families.

This event is Thursday, Dec. 4, from 4-7 p.m. Register here.

Dec. 8 — Pumps & Pipes Annual Event 2025

The annual gathering brings together cross-industry leaders in aerospace, energy and medicine for engaging discussions and networking opportunities. Connor Grennan, Chief AI Architect at the NYU Stern School of Business, will present this year's keynote address, entitled "Practical Strategies to Increase Productivity." Other sessions will feature leaders from Cena Research Institute, NASA Ames Research Center, ExxonMobil, Southwest Airlines and more.

This event is Monday, Dec. 8, from 8 a.m.-5 p.m., at TMC Helix Park. Register here.

Dec. 9 — Jingle and Mingle

Don your ugliest sweater and snap a pic with Startup Santa! Bayou City Startups, Rocket Network, Founder Institute and Energytech Nexus are bringing back their popular Jingle Mingle for the third year. Network and celebrate with founders, community stakeholders and others in Houston's innovation scene. Donations to the Houston Food Bank are encouraged in place of tickets.

This event is Tuesday, Dec. 9, from 5-7 p.m., at the Solarium in Midtown. Register here.

Dec. 9 — European Innovation Spotlight

Celebrate European cooperation and innovation with the European Innovation Council during an exclusive demo night and networking event at Greentown Labs. Hear from 15 EIC-backed founders supported by the European Union with top-class climatetech technologies, listen to a fireside chat and engage in a networking event following the pitches.

This event is Tuesday, Dec. 9, from 4:30-7 p.m., at the Ion. Register here.

Dec. 9-10 — Energy LIVE

Energy LIVE is Reuters Events' flagship ConfEx that brings the full energy ecosystem together under one roof to solve the industry's most urgent commercial and operational challenges. The event will feature 3,000-plus senior executives across three strategic stages, a showcase of 75-plus exhibitors and six strategic content pillars.

This event is Dec. 9-10 at NRG Park. Register here.

Dec. 15 — Innov8 Hub Pitch Day

Hear pitches from members of the latest Innov8 Hub Innovators to Founders cohort, which empowers academic scientists and innovators to become successful startup founders. Meet and network with the founders over light bites and drinks at a reception following the pitch competition.

This event is Monday, Dec. 15, at the Innovation Center at UH Technology Bridge (Bldg. 4). Register here.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME

Trending Topics